The literature has underlined an association between HER2 activating mutations in colorectal cancer and resistance to therapy. While these mutations reduce the efficacy of EGFR antibody agents such as cetuximab the tumors remain responsive to dual HER2 targeted therapy with tyrosine kinase inhibitors like neratinib(1). Additionally, while we detect activating mutations in about 7% of […]
Featured Contributor
Avani Patel
Avani Patel, MD, MHA is a psychiatry resident at the University of Mississippi Medical Center. She currently serves on the American Medical Association Ambassador Steering Committee. Read posts by Avani.
